Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes.
OBJECTIVE
To assess the ability of rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) to function as antigen-presenting cells (APCs) for arthritogenic autoantigens found within inflamed joint tissues.


METHODS
Human class II major histocompatibility complex (MHC)-typed FLS were used as APCs for murine class II MHC-restricted CD4 T cell hybridomas. Interferon-gamma (IFNgamma)-treated, antigen-loaded FLS were cocultured with T cell hybridomas specific for immunodominant portions of human cartilage gp-39 (HC gp-39) or human type II collagen (CII). T cell hybridoma activation was measured by enzyme-linked immunosorbent assay of culture supernatants for interleukin-2. Both synthetic peptide and synovial fluid (SF) were used as sources of antigen. APC function in cocultures was inhibited by using blocking antibodies to human class II MHC, CD54, or CD58, or to murine CD4, CD11a, or CD2.


RESULTS
Human FLS could present peptides from the autoantigens HC gp-39 and human CII to antigen-specific MHC-restricted T cell hybridomas. This response required pretreatment of FLS with IFNgamma, showed MHC restriction, and was dependent on human class II MHC and murine CD4 for effective antigen presentation. Furthermore, FLS were able to extract and present antigens found within human SF to both the HC gp-39 and human CII T cell hybridomas in an IFNgamma-dependent and MHC-restricted manner.


CONCLUSIONS
RA FLS can function as APCs and are able to present peptides derived from autoantigens found within joint tissues to activated T cells in vitro. In the context of inflamed synovial tissues, FLS may be an important and hitherto overlooked subset of APCs that could contribute to autoreactive immune responses.
Tran
Chinh N
CN
University of Michigan Rheumatic Disease Core Center, Ann Arbor, USA.
Davis
Michael J
MJ
Tesmer
Laura A
LA
Endres
Judith L
JL
Motyl
Christopher D
CD
Smuda
Craig
C
Somers
Emily C
EC
Chung
Kevin C
KC
Urquhart
Andrew G
AG
Lundy
Steven K
SK
Kovats
Susan
S
Fox
David A
DA
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000473:pathology; D001324:Autoantigens / Q000378:metabolism*; D015704:CD4 Antigens / Q000276:immunology / Q000378:metabolism; D023201:CD40 Ligand / Q000276:immunology* / Q000378:metabolism; D002478:Cells, Cultured; D024043:Collagen Type II / Q000276:immunology / Q000378:metabolism; D005347:Fibroblasts / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D000949:Histocompatibility Antigens Class II / Q000276:immunology / Q000378:metabolism; D006801:Humans; D006825:Hybridomas / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D007371:Interferon-gamma / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D013583:Synovial Membrane / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology
D001324:Autoantigens; D015704:CD4 Antigens; D024043:Collagen Type II; D000949:Histocompatibility Antigens Class II; D023201:CD40 Ligand; D007371:Interferon-gamma